Trial Profile
Phase II study of RG1415(erlotinib hydrochloride) as first-line treatment for non-small cell lung cancer(NSCLC) patients with epidermal growth factor receptor (EGFR) mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 May 2016
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Chugai Pharmaceutical
- 27 May 2016 New trial record